Francesco Bonella

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1235219/publications.pdf

Version: 2024-02-01

163	5,427	76326	98798
papers	citations	40 h-index	67 g-index

185	185	185	5153
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	ERS clinical practice guidelines on treatment of sarcoidosis. European Respiratory Journal, 2021, 58, 2004079.	6.7	248
2	Pulmonary alveolar proteinosis. Nature Reviews Disease Primers, 2019, 5, 16.	30.5	244
3	Significance of Bronchoalveolar Lavage for the Diagnosis of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 1043-1047.	5.6	200
4	Interstitial lung disease. European Respiratory Review, 2014, 23, 40-54.	7.1	182
5	Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis. An International Modified Delphi Survey. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1036-1044.	5.6	174
6	Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis. Respiratory Medicine, 2014, 108, 1031-1039.	2.9	163
7	Phenotypes of organ involvement in sarcoidosis. European Respiratory Journal, 2018, 51, 1700991.	6.7	146
8	Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs). Annals of the Rheumatic Diseases, 2021, 80, 143-150.	0.9	120
9	Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. Journal of Clinical Medicine, 2019, 8, 2013.	2.4	118
10	Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respiratory Research, 2015, 16, 116.	3.6	114
11	Chronic Hypersensitivity Pneumonitis. Clinics in Chest Medicine, 2012, 33, 151-163.	2.1	106
12	European IPF Patient Charter: unmet needs and a call to action for healthcare policymakers. European Respiratory Journal, 2016, 47, 597-606.	6.7	101
13	Whole lung lavage therapy for pulmonary alveolar proteinosis: a global survey of current practices and procedures. Orphanet Journal of Rare Diseases, 2016, 11, 115.	2.7	100
14	Differential diagnosis of usual interstitial pneumonia: when is it truly idiopathic?. European Respiratory Review, 2014, 23, 308-319.	7.1	99
15	Bronchoalveolar Lavage in Other Interstitial Lung Diseases. Seminars in Respiratory and Critical Care Medicine, 2007, 28, 514-524.	2.1	98
16	Pulmonary alveolar proteinosis: New insights from a single-center cohort of 70 patients. Respiratory Medicine, 2011, 105, 1908-1916.	2.9	98
17	<scp>MUC</scp>5<scp>B</scp> promoter polymorphism in <scp>J</scp>apanese patients with idiopathic pulmonary fibrosis. Respirology, 2015, 20, 439-444.	2.3	95
18	Differential diagnosis of granulomatous lung disease: clues and pitfalls. European Respiratory Review, 2017, 26, 170012.	7.1	95

#	Article	IF	Citations
19	Therapeutic targets in idiopathic pulmonary fibrosis. Respiratory Medicine, 2017, 131, 49-57.	2.9	92
20	Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 199-208.	5.6	90
21	Diagnostic Modalities in Sarcoidosis: BAL, EBUS, and PET. Seminars in Respiratory and Critical Care Medicine, 2010, 31, 404-408.	2.1	89
22	Diagnosis of Sarcoidosis. Clinical Reviews in Allergy and Immunology, 2015, 49, 54-62.	6.5	86
23	Unmet needs in the treatment of idiopathic pulmonary fibrosisâ€•insights from patient chart review in five European countries. BMC Pulmonary Medicine, 2017, 17, 124.	2.0	77
24	Hypersensitivity pneumonitis. Nature Reviews Disease Primers, 2020, 6, 65.	30.5	75
25	Serum KLâ€6 concentrations as a novel biomarker of severe COVIDâ€19. Journal of Medical Virology, 2020, 92, 2216-2220.	5.0	74
26	CCL18 in serum, BAL fluid and alveolar macrophage culture supernatant inÂinterstitial lung diseases. Respiratory Medicine, 2013, 107, 1444-1452.	2.9	73
27	Patients with IPF and lung cancer: diagnosis and management. Lancet Respiratory Medicine,the, 2018, 6, 86-88.	10.7	67
28	Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis. Thorax, 2017, 72, 148-153.	5.6	66
29	GATA2 deficiency in children and adults with severe pulmonary alveolar proteinosis and hematologic disorders. BMC Pulmonary Medicine, 2015, 15, 87.	2.0	63
30	Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone. Respiration, 2017, 93, 415-423.	2.6	63
31	Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis. New England Journal of Medicine, 2020, 383, 1635-1644.	27.0	61
32	Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives. BioMed Research International, 2015, 2015, 1-10.	1.9	60
33	Different MUC1 gene polymorphisms in German and Japanese ethnicities affect serum KL-6 levels. Respiratory Medicine, 2012, 106, 1756-1764.	2.9	54
34	Biomarkers in Connective Tissue Disease-Associated Interstitial Lung Disease. Seminars in Respiratory and Critical Care Medicine, 2014, 35, 181-200.	2.1	54
35	Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis. Respiration, 2016, 92, 98-106.	2.6	52
36	The Burden of Sarcoidosis Symptoms from a Patient Perspective. Lung, 2019, 197, 155-161.	3.3	52

#	Article	IF	Citations
37	Macrolides inhibit cytokine production by alveolar macrophages in bronchiolitis obliterans organizing pneumonia. Immunobiology, 2013, 218, 930-937.	1.9	51
38	Update on therapeutic management of idiopathic pulmonary fibrosis. Therapeutics and Clinical Risk Management, 2015, 11, 359.	2.0	51
39	Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis. European Journal of Cancer, 2020, 131, 18-26.	2.8	50
40	German Guideline for Idiopathic Pulmonary Fibrosis â€“ Update on Pharmacological Therapies 2017. Pneumologie, 2018, 72, 155-168.	0.1	47
41	Chest radiography or computed tomography for COVID-19 pneumonia? Comparative study in a simulated triage setting. European Respiratory Journal, 2021, 58, 2004188.	6.7	47
42	Krebs von den Lungen-6 as a biomarker for disease severity assessment in interstitial lung disease: a comprehensive review. Biomarkers in Medicine, 2020, 14, 665-674.	1.4	44
43	Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis. Respiration, 2018, 95, 317-326.	2.6	42
44	The Management of Patients With Idiopathic Pulmonary Fibrosis. Frontiers in Medicine, 2018, 5, 148.	2.6	42
45	Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis. Respiration, 2018, 96, 314-322.	2.6	41
46	Serum KL-6 is a predictor of outcome in pulmonary alveolar proteinosis. Orphanet Journal of Rare Diseases, 2013, 8, 53.	2.7	39
47	Serum YKL-40 as predictor of outcome in hypersensitivity pneumonitis. European Respiratory Journal, 2017, 49, 1501924.	6.7	38
48	Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib. Drug Design, Development and Therapy, 2015, 9, 6407.	4.3	37
49	Coagulation factor XII regulates inflammatory responses in human lungs. Thrombosis and Haemostasis, 2017, 117, 1896-1907.	3.4	36
50	Nailfold Capillaroscopy Characteristics of Antisynthetase Syndrome and Possible Clinical Associations: Results of a Multicenter International Study. Journal of Rheumatology, 2019, 46, 279-284.	2.0	36
51	When the Game Changes. Chest, 2020, 158, 892-895.	0.8	36
52	Gaps in care of patients living with pulmonary fibrosis: a joint patient and expert statement on the results of a Europe-wide survey. ERJ Open Research, 2019, 5, 00124-2019.	2.6	33
53	A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis. Chest, 2020, 157, 1506-1512.	0.8	33
54	Wash-out kinetics and efficacy of a modified lavage technique for alveolar proteinosis. European Respiratory Journal, 2012, 40, 1468-1474.	6.7	31

#	Article	IF	Citations
55	Timing of onset affects arthritis presentation pattern in antisyntethase syndrome. Clinical and Experimental Rheumatology, 2018, 36, 44-49.	0.8	30
56	Angiogenic and Angiostatic Chemokines in Idiopathic Pulmonary Fibrosis and Granulomatous Lung Disease. Respiration, 2010, 80, 372-378.	2.6	29
57	Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSISÂtrials. European Respiratory Journal, 2019, 54, 1801797.	6.7	28
58	Diagnostic approach to interstitial pneumonias in a single centre: report on 88 cases. Diagnostic Pathology, 2012, 7, 160.	2.0	27
59	Hypersensitivity Pneumonitis. Immunology and Allergy Clinics of North America, 2012, 32, 537-556.	1.9	26
60	FAM13A polymorphism as a prognostic factor in patients with idiopathic pulmonary fibrosis. Respiratory Medicine, 2017, 123, 105-109.	2.9	25
61	Quantitative Lipidomics in Pulmonary Alveolar Proteinosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 881-887.	5.6	25
62	Potential clinical utility of MUC5B und TOLLIP single nucleotide polymorphisms (SNPs) in the management of patients with IPF. Orphanet Journal of Rare Diseases, 2021, 16, 111.	2.7	25
63	Comparison of serum KL-6 versus bronchoalveolar lavage neutrophilia for the diagnosis of bronchiolitis obliterans in lung transplantation. Journal of Heart and Lung Transplantation, 2011, 30, 1374-1380.	0.6	24
64	Differences in serum SP-D levels between German and Japanese subjects are associated with SFTPDgene polymorphisms. BMC Medical Genetics, 2014, 15, 4.	2.1	22
65	MUC1 gene polymorphisms are associated with serum KL-6 levels and pulmonary dysfunction in pulmonary alveolar proteinosis. Orphanet Journal of Rare Diseases, 2016, 11, 48.	2.7	22
66	The DIAMORFOSIS (DIAgnosis and Management Of lung canceR and FibrOSIS) survey: international survey and call for consensus. ERJ Open Research, 2021, 7, 00529-2020.	2.6	22
67	Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities. Respiratory Research, 2021, 22, 125.	3.6	22
68	Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis: Uncertainties and Controversies. Respiration, 2018, 96, 571-587.	2.6	21
69	A Global Survey on Whole Lung Lavage in Pulmonary Alveolar Proteinosis. Chest, 2016, 150, 251-253.	0.8	20
70	Facts and promises on lung biomarkers in interstitial lung diseases. Expert Review of Respiratory Medicine, 2015, 9, 437-457.	2.5	19
71	New insights on patient-reported outcome measures in idiopathic pulmonary fibrosis. Current Opinion in Pulmonary Medicine, 2016, 22, 434-441.	2.6	19
72	S2K Guideline for Diagnosis of Idiopathic Pulmonary Fibrosis. Respiration, 2021, 100, 238-271.	2.6	19

#	Article	IF	Citations
73	Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here?. European Respiratory Review, 2021, 30, 210026.	7.1	17
74	Misconceptions regarding symptoms of sarcoidosis. Lancet Respiratory Medicine,the, 2021, 9, 816-818.	10.7	16
75	Idiopathic pulmonary fibrosis: Physician and patient perspectives on the pathway to care from symptom recognition to diagnosis and disease burden. Respirology, 2022, 27, 66-75.	2.3	16
76	Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases. Respirology, 2022, 27, 294-300.	2.3	15
77	Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 247-259.	5.6	15
78	Omeprazole reduces the response to capsaicin but not to methacholine in asthmatic patients with proximal reflux. Scandinavian Journal of Gastroenterology, 2007, 42, 299-307.	1.5	14
79	Serum <scp>YKL</scp>â€40 is a reliable biomarker for pulmonary alveolar proteinosis. Respirology, 2017, 22, 1371-1378.	2.3	14
80	Shaping the future of an ultra-rare disease. Current Opinion in Pulmonary Medicine, 2019, 25, 450-458.	2.6	14
81	Azathioprine for Connective Tissue Disease-Associated Interstitial Lung Disease. Respiration, 2020, 99, 628-636.	2.6	12
82	Adiponectin and leptin levels in idiopathic pulmonary fibrosis: A new method for BAL and serum assessment. Immunobiology, 2020, 225, 151997.	1.9	12
83	Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases. Advances in Therapy, 2022, 39, 3392-3402.	2.9	12
84	Acid reflux into the oesophagus does not influence exercise-induced airway narrowing in bronchial asthma. British Journal of Sports Medicine, 2008, 42, 545-549.	6.7	11
85	Looking into the future of sarcoidosis: what is next for treatment?. Current Opinion in Pulmonary Medicine, 2020, 26, 598-607.	2.6	10
86	The perpetual enigma of bronchoalveolar lavage fluid lymphocytosis in chronic hypersensitivity pneumonitis: is it of diagnostic value?. European Respiratory Journal, 2020, 56, 2001534.	6.7	10
87	Late Breaking Abstract - Exploring Efficacy and Safety of oral Pirfenidone for progressive, non-IPF Lung Fibrosis (RELIEF). , 2019, , .		10
88	Genetic testing in interstitial lung disease: An international survey. Respirology, 0, , .	2.3	10
89	European idiopathic pulmonary fibrosis Patient Charter: a missed opportunity. European Respiratory Journal, 2016, 48, 283-284.	6.7	8
90	Idiopathic pleuroparenchymal fibroelastosis (PPFE) â€“ A case study of a rare entity. Revista Portuguesa De Pneumologia, 2017, 23, 352-355.	0.7	8

#	Article	IF	Citations
91	Baseline High-Resolution CT Findings Predict Acute Exacerbation of Idiopathic Pulmonary Fibrosis: German and Japanese Cohort Study. Journal of Clinical Medicine, 2019, 8, 2069.	2.4	8
92	Efficacy, safety, and tolerability of combined pirfenidone and N-acetylcysteine therapy: a systematic review and meta-analysis. BMC Pulmonary Medicine, 2020, 20, 128.	2.0	8
93	Shedding light on developmental drugs for idiopathic pulmonary fibrosis. Expert Opinion on Investigational Drugs, 2020, 29, 797-808.	4.1	8
94	Patient Reported Experiences and Delays During the Diagnostic Pathway for Pulmonary Fibrosis: A Multinational European Survey. Frontiers in Medicine, 2021, 8, 711194.	2.6	8
95	Alveolar and intraparenchymal proteasome in sarcoidosis. Respiratory Medicine, 2014, 108, 1534-1541.	2.9	7
96	Pulmonary alveolar proteinosis in a cat. BMC Veterinary Research, 2015, 11, 302.	1.9	7
97	KL-6, a Human MUC1 Mucin, as a prognostic marker for diffuse alveolar hemorrhage syndrome. Orphanet Journal of Rare Diseases, 2012, 7, 99.	2.7	5
98	The Ambitious Goal of Validating Prognostic Biomarkers for Systemic Sclerosis-related Interstitial Lung Disease. Journal of Rheumatology, 2013, 40, 1034-1036.	2.0	5
99	An Important Step Forward, but Still a Way to Go. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 340-341.	5.6	5
100	Utility of Anti-DSF70 Antibodies to Predict Connective Tissue Disease in Patients Originally Presenting with Idiopathic Interstitial Pneumonia. Respiration, 2019, 98, 29-37.	2.6	5
101	Research highlights from the 2018 ERS International Congress: interstitial lung diseases. ERJ Open Research, 2019, 5, 00215-2018.	2.6	5
102	Changes in serum KL-6 levels are associated with the development of chronic lung allograft dysfunction in lung transplant recipients. Transplant Immunology, 2019, 52, 40-44.	1.2	5
103	Unclassifiable, or simply unclassified interstitial lung disease?. Current Opinion in Pulmonary Medicine, 2021, 27, 405-413.	2.6	5
104	Biomarker discovery in systemic sclerosis: state of the art. Current Biomarker Findings, 2015, , 47.	0.4	4
105	Extracellular 20S proteasome in BAL and serum of patients with alveolar proteinosis. Immunobiology, 2015, 220, 382-388.	1.9	4
106	New guideline on treatment of idiopathic pulmonary fibrosis. Lancet Respiratory Medicine,the, 2015, 3, e31-e32.	10.7	4
107	Daily Home Spirometry: A New Milestone in the Field of Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1033-1034.	5.6	4
108	Pulmonary alveolar proteinosis. Pneumologia, 2014, 63, 144, 147-55.	0.1	4

#	Article	IF	Citations
109	Whole-Lung Lavage: A Successful Treatment for Restoring Acinar Ventilation Distribution in Primary Acquired Pulmonary Alveolar Proteinosis. Respiration, 2012, 84, 70-74.	2.6	3
110	A female soccer player with recurrent haemoptysis and iron deficiency anaemia: idiopathic pulmonary haemosiderosis (IPH)–case report and literature review. BMJ Case Reports, 2010, 2010, bcr0620091969-bcr0620091969.	0.5	3
111	Current and Future Therapies for Idiopathic Pulmonary Fibrosis. Pulmonary Therapy, 2015, 1, 1-18.	2.2	2
112	Comparative analysis of multiple gene polymorphisms for acute exacerbation of idiopathic pulmonary fibrosis. , 2015, , .		2
113	Diagnosis and therapy of acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF) in Germany. , 2018, , .		2
114	Significance of pulmonary involvement in systemic sclerosis (SSc)â€“ data from the German SSc-network. , 2018, , .		2
115	Long term outcomes of immunomodulatory drugs in SSc-ILD - data from the German SSc-network. , 2019, , .		2
116	Communicating with patients with IPF: can we do it better?. ERJ Open Research, 2022, 8, 00422-2021.	2.6	2
117	Targeted therapy for pulmonary alveolar proteinosis: the time is now. European Respiratory Journal, 2022, 59, 2102971.	6.7	2
118	A Multicenter, International Evaluation Of Blood Testing For The Diagnosis Of Autoimmune Pulmonary Alveolar Proteinosis. , 2011, , .		1
119	European Respiratory Society International Congress 2017: highlights from the Clinical Assembly. ERJ Open Research, 2018, 4, 00134-2017.	2.6	1
120	Pulmonary Function Tests in Idiopathic Pulmonary Fibrosis. Respiratory Medicine, 2019, , 85-95.	0.1	1
121	Effect of metformin on clinically relevant outcomes in patients with idiopathic pulmonary fibrosis (IPF). , 2017, , .		1
122	Late Breaking Abstract - The DIAMORFOSIS (DIAgnosis and Management Of lung canceR and FibrOSIS) survey. , 2019, , .		1
123	Does anti-acid treatment influence disease progression in SSc-ILD ? data from the German SSc-network. , 2019, , .		1
124	Efficacy and safety of nintedanib in the elderly patient with IPF. , 2019, , .		1
125	Potential clinical utility of MUC5B and TOLLIP single nucleotide polymorphisms (SNP) in in the management of patients with IPF. , 2019, , .		1
126	Whole lung lavage therapy (WLL) of pulmonary alveolar proteinosis (PAP): A global survey of current practices and procedures. , 2016, , .		1

#	Article	IF	Citations
127	Lung involvement and clinical characteristics in anti-MDA5 positive connective tissue diseases. , 2018, , .		1
128	Biomarkers. , 0, , 122-142.		1
129	Pulmonary sarcoidosis. , 2022, , 122-141.		1
130	Defining anti-synthetase syndrome: a systematic literature review.. Clinical and Experimental Rheumatology, 2022, 40, 309-319.	0.8	1
131	To BAL or Not to BAL: Is This a Problem in Diagnosing IPF?. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 380-380.	5.6	0
132	Serum Levels Of KL-6, A Biomarker For Interstitial Lung Diseases, In Caucasian Patients With Idiopathic Interstitial Pneumonias. , 2010, , .		0
133	Serum Levels Of YKL-40, An Interstitial Lung Disease Biomarker, In Patients With Autoimmune Alveolar Proteinosis. , 2010, , .		0
134	Serum KL-6 As Predictor Of Disease Progression In Patients With Pulmonary Alveolar Proteinosis. , 2011, , .		0
135	Serum Kl-6 Is A Useful Diagnostic And Prognostic Biomarker In Idiopathic Interstitial Pneumonia In German Patients. , 2011, , .		0
136	Selfâ€reported asthma and respiratory symptoms among Italian amateur athletes. European Journal of Sport Science, 2012, 12, 96-102.	2.7	0
137	How to handle IPF â€“ the new Portuguese consensus document. Revista Portuguesa De Pneumologia, 2016, 22, 70-72.	0.7	0
138	Serum YKLâ€40 in workers at an indiumâ€tin oxide production facility â€“ Reply. Respirology, 2018, 23, 342-342.	2.3	0
139	THU0339â€…PULMONARY INVOLVEMENT AND OUTCOME IN SYSTEMIC SCLEROSIS (SSC) â€“ ILD-PH AS AN IMPORTANT SUBSET. , 2019, , .		0
140	ERS International Congress, Madrid, 2019: highlights from the Interstitial Lung Diseases Assembly. ERJ Open Research, 2020, 6, 00143-2020.	2.6	0
141	A New Tool to Assess Quality of Life in Patients with Idiopathic Pulmonary Fibrosis or Non-specific Interstitial Pneumonia. Pneumologie, 2022, 76, 25-34.	0.1	0
142	Pulmonale Alveolarproteinose. , 2015, , 1-7.		0
143	Effect of nintedanib on the release of angiogenic/angiostatic cytokines by alveolar macrophages (AMs) in interstitial lung diseases (ILD). , 2015, , .		0
144	Serum KL-6 as a biomarker to assess response to azathioprine in connective tissue disease associated lung disease (CTD-ILD). , 2015, , .		0

#	Article	IF	Citations
145	Determination of a single nucleotide polymorphism (SNP) of the TNFalpha-R1 region (TNFRSF1A) in patients with lung sarcoidosis: Preliminary results. , 2015, , .		0
146	Different biopsy techniques for confirmation of sarcoidosis: The game for the best diagnostic yield is still open. , 2015, , .		0
147	Sporadic idiopathic non-specific interstitial pneumonia in monozygotic twin sisters. , 2015, , .		0
148	Is it possible to predict the outcome of the whole lung lavage (WLL) in pulmonary alveolar proteinosis (PAP)?. , 2015, , .		0
149	Pulmonale Alveolarproteinose. , 2016, , 237-245.		0
150	LSC Abstract â€“ Is it possible to predict the outcome of the whole lung lavage (WLL) in pulmonary alveolar proteinosis (PAP)?. , 2016, , .		0
151	Inhaled rhGM-CSF (molgramostim) in the first randomised, double-blind, placebo-controlled, international trial in patients with autoimmune alveolar proteinosis (aPAP). , 2016, , .		0
152	Detection of anti DFS70 antibodies in patients with interstitial lung disease (ILD) with and without connective tissue disease (CTD). , 2016, , .		0
153	Nintedanib for idiopathic pulmonary fibrosis (IPF): Data from the German compassionate use program (CUP). , 2016, , .		0
154	Extracorporeal membrane oxygenation for the treatment of acute exacerbation of interstitial lung diseases. , 2017, , .		0
155	A gene network to predict the clinical response to whole lung lavage (WLL), in pulmonary alveolar proteinosis (PAP). , 2017, , .		0
156	Diffusing capacity (DLCO) as a potential surrogate marker for scleroderma related lung diseaseâ€“data from the german network for systemic sclerosis. , 2017, , .		0
157	IL-9 and IL-9 receptor (IL-9r) expression in BALF lymphocytes in ILD patients: preliminary results. , 2017, , .		0
158	Serum anti DFS70 antibody titer and lung functional impairment in patients with interstitial lung disease (ILD). , 2017, , .		0
159	Modified GAP stage as a predictor of acute exacerbation in idiopathic pulmonary fibrosis. , 2018, , .		0
160	Nailfold capillaroscopy findings in ILD patients: results from a single centre investigation.. , 2018, , .		0
161	Characterization of the gene network driving the whole lung lavage (WLL) outcome in Pulmonary Alveolar Proteinosis (PAP).. , 2018, , .		0
162	Serum KL-6 as a biomarker for interstitial lung diseases in a clinical setting: application of a fully automated immunoassay. , 2019, , .		0

#	Article	IF	Citations
163	ERS International Congress 2021: highlights from the Interstitial Lung Diseases Assembly. ERJ Open Research, 0, , 00640-2021.	2.6	0